Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alejandro Arana

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Current Medical Research and Opinion|February 16, 2021
A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladderKelesitse Phiri, Jesper Hallas, Marie Linder, et al.
Pharmacoepidemiology and Drug Safety|April 29, 2024
Lessons learned from a multi-data source research collaboration: The mirabegron post-authorization safety study programStefan de Vogel, John D Seeger, Alejandro Arana, et al.
Therapeutic Advances in Psychopharmacology|September 2, 2025
Frequency of anticholinergic drug use in patients treated with aripiprazole once-monthly: a 2-year cohort study using European healthcare databasesFrank Andersohn, Pedro Such, Michael Jan, et al.
Pharmacoepidemiology and Drug Safety|January 31, 2017
Characterization of new users of cilostazol in the UK, Spain, Sweden, and GermanyJordi Castellsague, Susana Perez-Gutthann, Brian Calingaert, et al.
Drug Safety|July 8, 2021
Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort StudyVeena Hoffman, Jesper Hallas, Marie Linder, et al.
Clinical Epidemiology|January 10, 2022
Long-Term Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus and Pimecrolimus: Final Results from the Extension of the Cohort Study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE)Alejandro Arana, Anton Pottegård, Josephina G Kuiper, et al.
Clinical Epidemiology|March 27, 2026
Harmonizing Case Validation for Vaccine Safety in Real-World Data: The VAC4EU ExperienceAmirreza Dehghan Tarazjani, Daniel Weibel, Taylor Aurelius, et al.
Pharmacoepidemiology and Drug Safety|August 15, 2024
Metadata for Data dIscoverability aNd Study rEplicability in obseRVAtional Studies (MINERVA): Lessons Learnt From the MINERVA Project in EuropeRosa Gini, Romin Pajouheshnia, Lia Gutierrez, et al.
Pharmacoepidemiology and Drug Safety|August 15, 2024
Metadata for Data dIscoverability aNd Study rEplicability in obseRVAtional Studies (MINERVA): Development and Pilot of a Metadata List and Catalogue in EuropeRomin Pajouheshnia, Rosa Gini, Lia Gutierrez, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Current Medical Research and Opinion|February 16, 2021
A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladderKelesitse Phiri, Jesper Hallas, Marie Linder, et al.
Pharmacoepidemiology and Drug Safety|April 29, 2024
Lessons learned from a multi-data source research collaboration: The mirabegron post-authorization safety study programStefan de Vogel, John D Seeger, Alejandro Arana, et al.
Therapeutic Advances in Psychopharmacology|September 2, 2025
Frequency of anticholinergic drug use in patients treated with aripiprazole once-monthly: a 2-year cohort study using European healthcare databasesFrank Andersohn, Pedro Such, Michael Jan, et al.
Pharmacoepidemiology and Drug Safety|January 31, 2017
Characterization of new users of cilostazol in the UK, Spain, Sweden, and GermanyJordi Castellsague, Susana Perez-Gutthann, Brian Calingaert, et al.
Drug Safety|July 8, 2021
Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort StudyVeena Hoffman, Jesper Hallas, Marie Linder, et al.
Clinical Epidemiology|January 10, 2022
Long-Term Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus and Pimecrolimus: Final Results from the Extension of the Cohort Study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE)Alejandro Arana, Anton Pottegård, Josephina G Kuiper, et al.
Clinical Epidemiology|March 27, 2026
Harmonizing Case Validation for Vaccine Safety in Real-World Data: The VAC4EU ExperienceAmirreza Dehghan Tarazjani, Daniel Weibel, Taylor Aurelius, et al.
Pharmacoepidemiology and Drug Safety|August 15, 2024
Metadata for Data dIscoverability aNd Study rEplicability in obseRVAtional Studies (MINERVA): Lessons Learnt From the MINERVA Project in EuropeRosa Gini, Romin Pajouheshnia, Lia Gutierrez, et al.
Pharmacoepidemiology and Drug Safety|August 15, 2024
Metadata for Data dIscoverability aNd Study rEplicability in obseRVAtional Studies (MINERVA): Development and Pilot of a Metadata List and Catalogue in EuropeRomin Pajouheshnia, Rosa Gini, Lia Gutierrez, et al.
Pageof 4